secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2022-02-16T23:59:59+00:00
Accession:  0001770787-22-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics reports FY 2021 revenue $490.5M (+64% YoY); guides FY 2022 revenue $600-630M
--------------------------------------------------------------------------------

- Revenue $490.5M FY 2021, up 64% from $298.8M in FY 2020; Q4 revenue $143.5M, up 28% from $112.2M.
- Gross margin 85% FY 2021 vs 80% in 2020, due to lower royalties and manufacturing efficiencies.
- Operating loss $52.3M FY 2021 vs $534.1M in 2020, which included $447.5M acquisition-related R&D charges.
- Net loss $58.2M FY 2021 vs $542.7M in 2020; cash and equivalents $587.4M as of Dec 31, 2021.
- FY 2022 revenue guidance $600-630M, representing 22-28% growth over FY 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078722000004/0001770787-22-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078722000004/txg-20220216.htm
  HTML page:      https://secwatch.observer/filing/0001770787-22-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer